Unlock instant, AI-driven research and patent intelligence for your innovation.

Bispecific heterodimeric diabodies and uses thereof

A bispecific, heterodimer technology, applied in the direction of antibodies, applications, specific peptides, etc., can solve problems such as poor stability characteristics, limited ineffective generation, etc.

Inactive Publication Date: 2017-05-10
PFIZER INC
View PDF6 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most efforts to generate such molecules have been limited by inefficient production and poor stability properties

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific heterodimeric diabodies and uses thereof
  • Bispecific heterodimeric diabodies and uses thereof
  • Bispecific heterodimeric diabodies and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0261] Generation of P-cadherin and bispecific heterodimeric diabodies

[0262] Bispecific heterodimeric diabodies were constructed to evaluate the recombinant production, purification and binding characteristics of each. Affinity-purified bispecific heterodimeric diabodies were produced by the recombinant expression system described herein. ELISA and SPR analysis also revealed that the covalent bispecific heterodimeric diabody had affinity for two target antigens, P-cadherin and CD-3, and was able to bind both antigens simultaneously.

[0263] A. Phage display

[0264] A phage display library consisting of scFv derived from non-immunized human donors was used to identify single chain fragment variable (scFv) portions that bind the extracellular domain (ECD) of P-cadherin using techniques known in the art. Binding of scFv expressed on the surface of phage was measured by standard ELISA techniques on P-Cadherin constructs and P-Cadherin expressing cells.

[0265] B. Sequ...

Embodiment 2

[0302] Construction of anti-P-cadherin / anti-human CD3 LP-DART

[0303] Anti-P-cadherin / anti-human CD3 DART proteins were amplified by PCR such that each DART protein contained restriction enzyme cloning sites at each end for cloning into mammalian expression vectors, see Table 11 and Figure 33A and 33B .

[0304] Table 11. Anti-P-Cadherin / anti-human CD3 DART proteins.

[0305]

[0306] Subsequently, a nucleic acid encoding a DART protein sequence is fused to each nucleic acid encoding a modified Fc construct such as a "button" Fc chain (SEQ ID NO: 63) and a "button" Fc chain (SEQ ID NO: 64), which Each is linked to the C-terminus of the DART with a cysteine ​​linker such as GCPPCP (SEQ ID NO: 73), GGTGGCPPCP (SEQ ID NO 74), GEPKSSDKTHTCPPCP (SEQ ID NO 75) and GGTGGGEPKSSDKTHTCPPCP (SEQ ID NO 76).

[0307] After PCR amplification, DART and Fc chain nucleic acids were digested with BspEI and HindIII (5' DART cloning site) or EcoRI (3' Fc cloning site). Digested DNA was i...

Embodiment 3

[0309] Binding properties of P-cadherin scFv-Fc and DART proteins

[0310] P-cadherin scFv-Fc constructs (P-cadherin VH and VL fused to the Fc region of human IgG) and DART proteins were analyzed with P-cadherin constructs and with expression of P-cadherin using standard ELISA techniques. Cell-binding properties of cohesins. The data in Table 12 indicate that the phage-derived P-Cadherin scFv-Fc constructs bind strongly to recombinant human P-Cadherin and have no detectable binding to mouse P-Cadherin.

[0311] Table 12. Binding properties of P-cadherin scFv-Fc to P-cadherin protein constructs.

[0312] P-CAD Clone# huP-cad-ECD EC50 (nM) huP-cad-ECD Biotinylated EC50(nM) muP-cad-ECD EC50 (nM) 33 scFv-Fc 3.464 0.1012 NB 34 scFv-Fc 11.16 0.1943 NB 35 scFv-Fc 2.5 0.01762 NB PF03732010 1.936 0.0188 2.333 negative control NB NB NB

[0313] NB = no detectable binding.

[0314] The binding properties of P-cadherin s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.

Description

[0001] related application [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 019,762, filed July 1, 2014, and U.S. Provisional Application No. 62 / 148,920, filed April 17, 2015, which are hereby incorporated by reference in their entirety . [0003] sequence listing [0004] This application is electronically filed via EFS-Web and includes the electronically filed Sequence Listing in .txt format. The .txt file contains a sequence listing created on June 12, 2015 titled "PC72054A_Sequence_Listing.txt" and 248 KB in size. The Sequence Listing contained in this .txt file is part of the specification and is hereby incorporated by reference in its entirety. [0005] field of invention [0006] The present invention relates to bispecific heterodimeric diabodies and their use in the treatment of cancer. [0007] Background of the invention [0008] Various strategies have been developed to generate bispecific molecules capable of recruiting T cell...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/46C07K16/18C07K16/28C12N15/13A61K39/395A61P35/00
CPCC07K16/18C07K16/2809C07K16/468A61K2039/505C07K2317/56C07K2317/565C07K2317/524C07K2317/526C07K2317/31C07K2317/94C07K2317/626C07K2317/72C07K2317/76C07K2317/732C07K16/28A61P35/00A61P43/00
Inventor C.M.梅A.R.鲁特W.A.布拉迪L.G.茨斯蒂亚科瓦L.莫斯亚克L.布卢姆P.A.摩尔L.S.约翰逊
Owner PFIZER INC